The integration of immune checkpoint inhibitors into first-line treatment has markedly improved outcomes for extensive-stage small cell lung cancer (ES-SCLC). Adebrelimab, a PD-L1 inhibitor, demonstrated superior overall survival in the phase 3 CAPSTONE-1 trial. We present a detailed case of a 62-year-old male with ES-SCLC who achieved a progression-free survival (PFS) of 33 months following a multimodal regimen of adebrelimab plus chemotherapy, consolidative thoracic radiotherapy, and maintenance immunotherapy. Despite low PD-L1 expression (TPS<1%), the patient exhibited profound and durable tumor regression, with the primary mass shrinking from 146×158×217 mm to 51×21 mm. Treatment was well-tolerated with only grade 1–2 adverse events. This report underscores the potential for long-term disease control with adebrelimab-based therapy even in biomarker-unselected populations and highlights the importance of combined modality strategies.
Introduction Neuroendocrine prostate cancer (NEPC) is an aggressive treatment-associated lineage state emerging with potent androgen receptor (AR) pathway inhibition. Although treatment-emergent NEPC is increasingly recognized, the transcriptional consequences of sustained AR sup…
Background Early identification of patients at high risk of anastomotic leak (AL) following esophagectomy is essential for improving surgical outcomes. However, reliable preoperative risk stratification remains challenging. This study aimed to predict AL risk in the esophageal ca…
Objective To describe the clinical, pathological, and therapeutic features of spontaneous rupture of a recurrent intracranial dermoid cyst (IDC), and to summarize relevant dermoid-specific literature. Methods We report a 38-year-old woman with a clinical history of resection of a…
Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE), a member of the serine/threonine kinase family, is an important oncogene in glioblastoma. IKBKE is involved in the progression of multiple tumours in glioblastoma (GBM), including tumour invasion, migration, and…
The advent of cancer immunotherapy has led to dramatically improved outcomes in several immunogenic adult cancers. Similar successes have been seen in some pediatric cancers, but only in specific settings. A particular challenge has been the application of immunotherapy approache…
Background and aim Liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC) within extended transplant criteria, but it is available to only a minority of patients. The optimal alternative treatment strategy for patients with HCC beyond th…